Biggest News Aggregation in the World
📰 Nasdaq Carm News

Page 2 - Nasdaq Carm News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Nasdaq Carm. Real-time updates on events, politics, business and more.

Short Interest in Carisma Therapeutics, Inc. (NASDAQ:CARM) Drops By 18.1%

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Rating) saw a significant decline in short interest in May. As of May 31st, there was short interest totalling 521,900 shares, a decline of 18.1% from the May 15th total of 636,900 shares. Approximately 3.2% of the shares of the stock are short sold. Based on an average daily […]
Robertw Baird Carisma Therapeutics Company Profile Stratos Wealth Partners Virtu Financial Carisma Therapeutics Inc Asset Management Inc

Carisma Therapeutics (CARM) vs. The Competition Critical Contrast

Carisma Therapeutics (NASDAQ:CARM – Get Rating) is one of 997 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Carisma Therapeutics to related businesses based on the strength of its earnings, analyst recommendations, profitability, risk, institutional ownership, valuation and dividends. Earnings & Valuation This […]
United States Michael Klichinsky Saar Gill Carisma Therapeutics Company Profile Carisma Therapeutics Inc Carisma Therapeutics
Source: wkrb13.com

Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk (NYSE:TLK) Downgraded by StockNews.com

Carisma Therapeutics (NASDAQ:CARM – Get Rating) was upgraded by stock analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, Marketbeat reports. The brokerage presently has a $7.00 price objective on the stock. Jefferies Financial Group’s price target would indicate a potential upside of […]
United States Michael Klichinsky Robertw Baird Saar Gill Connor Clark Lunn Investment Management Ltd Asset Management Inc

Carisma Therapeutics (NASDAQ:CARM) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Carisma Therapeutics (NASDAQ:CARM – Get Rating) in a research note released on Wednesday morning, Marketbeat.com reports. They currently have a $10.00 target price on the stock. HC Wainwright also issued estimates for Carisma Therapeutics’ Q2 2023 earnings at ($0.66) EPS, Q3 2023 earnings at ($0.71) EPS, […]
United States Michael Klichinsky Robertw Baird Saar Gill Deuterium Capital Management Blackrock Inc
Source: wkrb13.com

Carisma Therapeutics (NASDAQ:CARM) and Synaptogenix (NASDAQ:SNPX) Critical Contrast

Carisma Therapeutics (NASDAQ:CARM – Get Rating) and Synaptogenix (NASDAQ:SNPX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability. Valuation & Earnings This table compares Carisma Therapeutics and Synaptogenix’s […]
United States New York Saar Gill Michael Klichinsky Stanford University Synaptogenix Inc

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Carisma Therapeutics (CARM) Set to Announce Earnings on Friday

Carisma Therapeutics (NASDAQ:CARM – Get Rating) will be posting its quarterly earnings results on Friday, May 12th. Carisma Therapeutics Stock Up 2.7 % Shares of CARM stock traded up $0.16 on Thursday, hitting $6.02. 84,394 shares of the stock were exchanged, compared to its average volume of 117,782. The company has a market capitalization of […]
United States Saar Gill Michael Klichinsky Robertw Baird Carisma Therapeutics Inc Carisma Therapeutics

Carisma Therapeutics (NASDAQ:CARM) Trading Up 0.3%

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Rating)’s share price traded up 0.3% during trading on Friday . The stock traded as high as $3.20 and last traded at $3.10. 40,007 shares were traded during mid-day trading, a decline of 56% from the average session volume of 90,607 shares. The stock had previously closed at $3.09. […]
United States Saar Gill Michael Klichinsky Carisma Therapeutics Inc Carisma Therapeutics Get Rating

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science